Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ataxin-10 is a cytoplasmic protein encoded by the ATXN10 gene, best known for its association with spinocerebellar ataxia type 10 (SCA10), a neurodegenerative disorder caused by expansion of a pentanucleotide (ATTCT) repeat in its intronic region[1][3][5]. Ataxin-10 plays roles in neuron survival, neuronal differentiation, and neuritogenesis, partially through activation of the mitogen-activated protein kinase (MAPK) cascade and interaction with G protein subunits[1][3][4]. It is also essential for proper cytokinesis and coordinates cell cycle events, interacting with mitotic regulators such as polo-like kinase 1 (Plk1) and Aurora B kinase[1]. In SCA10, toxic intronic RNA expansions sequester RNA-binding proteins, leading to RNA processing defects and apoptosis. Ataxin-10 is broadly expressed, with particular importance during embryonic development and in the nervous system. There are no known direct interacting drugs as of the latest reports, and it is not currently a validated therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ataxin-10 (ATXN10).